Clinical Trial Update: A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome [Phase 3]

View source ↗

Summary

Phase 3 study evaluating relacorilant in endogenous Cushing syndrome completed with results posted on 2025-04-24.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Syndrome

Drugs mentioned

• Relacorilant (relacorilant)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Cushing Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2025-04-24